Alps Advisors Inc Allakos Inc. Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.6 - $6.14 $146,442 - $345,829	-56,324 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $33,192 - $64,098	-6,534 Reduced 10.39%	56,324 $321,000
Q4 2021 Feb 09, 2022	BUY	$8.55 - $111.89 $537,435 - $7.03 Million	62,858 New	62,858 $615,000
Q4 2020 Feb 03, 2021	SELL	$79.58 - $152.45 $4.96 Million - $9.51 Million	-62,375 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$66.43 - $90.99 $275,352 - $377,153	-4,145 Reduced 6.23%	62,375 $5.08 Million
Q2 2020 Aug 05, 2020	SELL	$44.04 - $80.69 $957,914 - $1.76 Million	-21,751 Reduced 24.64%	66,520 $4.78 Million
Q1 2020 May 06, 2020	BUY	$44.49 - $93.39 $326,823 - $686,042	7,346 Added 9.08%	88,271 $3.93 Million
Q4 2019 Feb 07, 2020	SELL	$66.49 - $137.73 $1.04 Million - $2.15 Million	-15,628 Reduced 16.19%	80,925 $7.72 Million
Q3 2019 Nov 04, 2019	BUY	$31.0 - $89.73 $207,483 - $600,562	6,693 Added 7.45%	96,553 $7.59 Million
Q2 2019 Aug 07, 2019	BUY	$36.0 - $44.73 $3.23 Million - $4.02 Million	89,860 New	89,860 $3.89 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.